News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 04, 2017, 09:00 ET CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics...

Dec 13, 2016, 09:00 ET CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered...

Nov 29, 2016, 07:00 ET CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

CytRx Corporation (NASDAQ:CYTR) today announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to ...

Nov 11, 2016, 09:00 ET CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial at the 2016 CTOS Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today presented a poster with...

Nov 09, 2016, 09:00 ET CytRx Reports Third Quarter 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for ...

Oct 10, 2016, 09:00 ET CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today presented results from its...

Sep 12, 2016, 09:00 ET CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that results from...

Sep 07, 2016, 09:00 ET CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached...

Sep 06, 2016, 09:00 ET CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Steven A....

Jul 29, 2016, 09:00 ET CytRx Reports Second Quarter 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for ...

Jul 15, 2016, 07:30 ET CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a ...

Jul 14, 2016, 05:12 ET CytRx Corporation Announces Proposed Public Offering of Common Stock and Warrants

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology today announced a proposed registered ...

Jul 11, 2016, 04:03 ET CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcoma; Subsequent Analysis to Be Announced Fourth Quarter 2016

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the results of an...

Jun 06, 2016, 09:00 ET CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the presentation of...

May 31, 2016, 09:00 ET CytRx to Present at Jefferies 2016 Global Healthcare Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Olivia Ware,...

May 11, 2016, 09:00 ET CytRx Reports First Quarter 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for ...

Apr 28, 2016, 09:00 ET CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that David Haen,...

Apr 25, 2016, 09:00 ET CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of...

Apr 20, 2016, 09:00 ET CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that three...

Apr 04, 2016, 09:00 ET CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has reached...

Mar 22, 2016, 09:00 ET CytRx to Present New Data Using Its Proprietary LADR™ Technology at the 2016 American Association for Cancer Research Annual Meeting

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will present ...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE

News from cytrx corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 04, 2017, 09:00 ET CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

Dec 13, 2016, 09:00 ET CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

Nov 29, 2016, 07:00 ET CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

Nov 11, 2016, 09:00 ET CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial at the 2016 CTOS Annual Meeting

Nov 09, 2016, 09:00 ET CytRx Reports Third Quarter 2016 Financial Results

Oct 10, 2016, 09:00 ET CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

Sep 12, 2016, 09:00 ET CytRx to Present Data at the European Society for Medical Oncology 2016 Congress from Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial

Sep 07, 2016, 09:00 ET CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer

Sep 06, 2016, 09:00 ET CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Jul 29, 2016, 09:00 ET CytRx Reports Second Quarter 2016 Financial Results

Jul 15, 2016, 07:30 ET CytRx Corporation Announces Pricing of $20 Million Public Offering of Common Stock and Warrants

Jul 14, 2016, 05:12 ET CytRx Corporation Announces Proposed Public Offering of Common Stock and Warrants

Jul 11, 2016, 04:03 ET CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcoma; Subsequent Analysis to Be Announced Fourth Quarter 2016

Jun 06, 2016, 09:00 ET CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting

May 31, 2016, 09:00 ET CytRx to Present at Jefferies 2016 Global Healthcare Conference

May 11, 2016, 09:00 ET CytRx Reports First Quarter 2016 Financial Results

Apr 28, 2016, 09:00 ET CytRx to Present at Joseph Gunnar and Co.'s PIONEERS 2016 Investor Conference

Apr 25, 2016, 09:00 ET CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year

Apr 20, 2016, 09:00 ET CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016

Apr 04, 2016, 09:00 ET CytRx Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis

Mar 22, 2016, 09:00 ET CytRx to Present New Data Using Its Proprietary LADR™ Technology at the 2016 American Association for Cancer Research Annual Meeting

Mar 11, 2016, 09:00 ET CytRx Reports 2015 Financial Results

Feb 29, 2016, 09:00 ET CytRx to Present at the Cowen & Company's 36th Annual Health Care Conference

Feb 08, 2016, 09:00 ET CytRx Secures $40 Million Long-Term Loan Facility

Feb 01, 2016, 09:00 ET CytRx to Present at the 18th Annual BIO CEO & Investor Conference

Journalists and Bloggers

The news you need, when you need it.

Contact Cision

Products

About

My Services